Shattuck Labs Inc. (NASDAQ:STTK) stock is down on Monday following news regarding its lead drug candidate, SL-325.

• Shattuck Labs stock is among today’s weakest performers. What’s weighing on STTK shares?

The company announced data from its Phase 1 clinical trial, which demonstrated encouraging results for inflammatory bowel disease, contributing to the stock’s upward momentum as the broader market sees gains, with S&P 500 futures up 0.7%.

Shattuck Labs is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases.

Read Also: Analyst Upgrade Boosts Shattuck On Confidence In Next-Gen Inflammatory Bowel Disease Therapy

STTK Stock Jumps On SL-325 Phase 1 Trial Results

Shattuck Labs has revealed positive data from its Phase 1 clinical trial of SL-325, a potential first-in-class antibody targeting the DR3 receptor, which could improve treatment outcomes for patients with inflammatory bowel disease.

The trial results indicate a favorable safety profile and effective receptor occupancy, setting the stage for further development in a Phase 2b trial expected to begin in the third quarter of 2026.

STTK Technical Analysis: Key Support, Resistance and RSI

The stock’s current price of $4.86 is significantly below its 20-day simple moving average (SMA) of $5.95, indicating potential resistance at that level.

The Relative Strength Index (RSI) is currently at 24.11, suggesting that the stock is in oversold territory, which may indicate a reversal or a bounce-back opportunity in the near term.

  • Key Resistance: $5 — Nearby level where rebounds can stall.
  • Key Support: $3.98 — 200-day SMA, which could provide a strong support level.

Analyst Consensus & Recent Actions: The stock carries a Buy rating with a consensus price target of $11.67. Recent analyst moves include:

  • Needham: Buy (Raises target to $17 on June 8)
  • HC Wainwright & Co.: Buy (Maintains target to $18 on June 8)
  • Citigroup: Upgraded to Buy (Target $7 on June 5)
  • Wedbush: Outperform (Raises target to $11 on May 8)

STTK Stock Price Activity: Shattuck Labs shares were down 11.59% at $4.05 at the time of publication on Monday, according to Benzinga Pro data.

Read Also: Jim Chanos Rejects SpaceX IPO Valuation Comparison To Amazon, Google, Meta's Early Days: 'Isn't Even Remotely True'

Photo: Billion Photos / Shutterstock